NCT06433804View on ClinicalTrials.gov

Clinicopathological Parameters of HER2 Low Breast Cancers

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

February 1, 2024

Conditions
HER2 Low Breast Cancers
Interventions
DIAGNOSTIC_TEST

HER2 IHC

Immunohistochemistry for HER2

Trial Locations (1)

Unknown

VMMC SJH, New Delhi

All Listed Sponsors
lead

Vardhman Mahavir Medical College And Safdarjung Hospital

OTHER

NCT06433804 - Clinicopathological Parameters of HER2 Low Breast Cancers | Biotech Hunter | Biotech Hunter